Literature DB >> 7256279

Novel single-pass exchange of circulating uridine in rat liver.

T Gasser, J D Moyer, R E Handschumacher.   

Abstract

Evidence is presented that the liver effects an essentially complete degradation of plasma uridine in a single pass and replaces it largely from hepatic pools of acid-soluble uridine nucleotides. The concentration of uridine in the hepatic vein of the rat was essentially the same as that in the arterial circulation and portal vein. However, the isolated perfused rat liver degraded more than 90 percent of infused [5-3H]uridine in a single passage. Similar results were found in vivo when tracer amounts of [3H]uridine and [14C]uridine were infused into the portal vein of an intact rat. Furthermore, less than 2 percent of the infused uridine entered the acid-soluble nucleotide pools of the liver after 30 minutes of infusion. Intraperitoneal injection of [3H]orotate allowed selective labeling of liver (and kidney) pyrimidines. After 3 hours, the specific activity of uridine in the hepatic vein was more than three times that in the arterial circulation. This unusual exchange, which is not saturated even at uridine concentrations as high as 50 microM, contributes to the rapid turnover of plasma uridine and explains its inefficient utilization in peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7256279     DOI: 10.1126/science.7256279

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  36 in total

1.  Coordination of the transcriptome and metabolome by the circadian clock.

Authors:  Kristin L Eckel-Mahan; Vishal R Patel; Robert P Mohney; Katie S Vignola; Pierre Baldi; Paolo Sassone-Corsi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

2.  Microarray analysis of newly synthesized RNA in cells and animals.

Authors:  M Kenzelmann; S Maertens; M Hergenhahn; S Kueffer; A Hotz-Wagenblatt; L Li; S Wang; C Ittrich; T Lemberger; R Arribas; S Jonnakuty; M C Hollstein; W Schmid; N Gretz; H J Gröne; G Schütz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-03       Impact factor: 11.205

Review 3.  Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses.

Authors:  Richard J Wurtman; Mehmet Cansev; Toshimasa Sakamoto; Ismael Ulus
Journal:  Nutr Rev       Date:  2010-12       Impact factor: 7.110

Review 4.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

5.  Metabolic engineering generates a transgene-free safety switch for cell therapy.

Authors:  Volker Wiebking; James O Patterson; Renata Martin; Monica K Chanda; Ciaran M Lee; Waracharee Srifa; Gang Bao; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2020-07-13       Impact factor: 54.908

6.  Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Authors:  J L Au; M G Wientjes; S L Bramer
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Nucleoside uptake in rat liver parenchymal cells.

Authors:  J Mercader; M Gomez-Angelats; B del Santo; F J Casado; A Felipe; M Pastor-Anglada
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

8.  Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation.

Authors:  Thuc T Le; Amy Ziemba; Yasuyo Urasaki; Eugene Hayes; Steven Brotman; Giuseppe Pizzorno
Journal:  J Lipid Res       Date:  2013-01-24       Impact factor: 5.922

9.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

Authors:  M Markman; T C Chan; S Cleary; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.